My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KALA BIO, Inc. - Common Stock (NQ:KALA)

1.530 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KALA BIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Here are the top movers in Tuesday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look.
Unusual volume stocks in Tuesday's session 
Via Chartmill
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition. 
Via Benzinga
Nasdaq Jumps 150 Points; US Pending Home Sales Rise
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened
The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving... 
Via Stocktwits
Topics Workforce
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companies 
From KALA BIO, Inc.
Via GlobeNewswire
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma. 
Via Benzinga
Kala Bio (KALA) Q2 Loss Widens 15%
Via The Motley Fool
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
From KALA BIO, Inc.
Via GlobeNewswire
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction
Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects. 
Via Stocktwits
Dow Drops More Than 400 Points After CPI Data
This morning's hotter-than-expected CPI data sent the market reeling, after the annual inflation rate rose to 3% and the 12-month core inflation rate rose to 3.3%. 
Via Talk Markets
Topics Economy Stocks Stocks / Equities
KALA BIO Announces Chief Executive Officer Transition
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Announces $10,750,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.